TRISALUS LIFE SCIENCES, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.72 USD | -3.38% |
|
-0.87% | -32.31% |
| 06-03 | TriSalus Life Sciences, Inc. Highlights Clinical Data from Phase 1b Perio-02 Trial | CI |
| 05-30 | Canaccord Genuity Initiates TriSalus Life Sciences at Buy Rating With $12 Price Target | MT |
Evolution of the average Target Price on TriSalus Life Sciences, Inc.
Price target over the last 5 years
History of analyst recommendation changes
dfaf7379b7884fc7b523073d0a.ub2AgEt-_VU-Rkd3gtvs8GMLTQ9-vBXa8GYiUOF6jok.i_Xq9BoGjmULDHYgyZ2pg1FUJV9G7XDiggN0G4c9-Mzh9PHmEzeqBgYEfw~c24c4243ea3f4a9f6a8e8409a3e2b08c
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
5.69
USD
Average target price
14.67
USD
Spread / Average Target
+157.76%
High Price Target
16
USD
Spread / Highest target
+181.20%
Low Price Target
12
USD
Spread / Lowest Target
+110.90%
Consensus detail
Consensus revision (last 18 months)
Analysts covering TriSalus Life Sciences, Inc.
| Canaccord Genuity |
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
- Stock Market
- Equities
- TLSI Stock
- Consensus TriSalus Life Sciences, Inc.
